The estimated Net Worth of Phillip John Brancazio is at least $221 Thousand dollars as of 4 May 2011. Phillip Brancazio owns over 67 units of Haemonetics stock worth over $221,117 and over the last 15 years Phillip sold HAE stock worth over $0.
Phillip has made over 3 trades of the Haemonetics stock since 2010, according to the Form 4 filled with the SEC. Most recently Phillip bought 67 units of HAE stock worth $3,136 on 4 May 2011.
The largest trade Phillip's ever made was buying 74 units of Haemonetics stock on 4 November 2010 worth over $3,429. On average, Phillip trades about 35 units every 62 days since 2009. As of 4 May 2011 Phillip still owns at least 3,052 units of Haemonetics stock.
You can see the complete history of Phillip Brancazio stock trades at the bottom of the page.
Phillip's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: